EP2561888 - Protein comprising NC-1 for treating angiogenesis-related diseases [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 31.01.2014 Database last updated on 03.09.2024 | Most recent event Tooltip | 31.01.2014 | Application deemed to be withdrawn | published on 05.03.2014 [2014/10] | Applicant(s) | For all designated states Deutsches Krebsforschungszentrum Im Neuenheimer Feld 280 69120 Heidelberg / DE | [2013/09] | Inventor(s) | 01 /
Lee, Tong-Yong. 10F-1, no3, Ln30, Qingnian Rd. Wanhua Sist. 108 Tapei City / TW | 02 /
Abdollahi, Amir. Werder Strasse 10 69120 Heidelberg / DE | 03 /
Javaherian, Kashi. 27 Webster Road Lexington. Massachusetts 02421 / US | [2013/09] | Representative(s) | Dick, Alexander Herzog Fiesser & Partner Patentanwälte PartG mbB Dudenstrasse 46 68167 Mannheim / DE | [N/P] |
Former [2013/09] | Dick, Alexander Herzog Fiesser & Partner Patentanwälte Dudenstrasse 46 68167 Mannheim / DE | Application number, filing date | 11178509.3 | 23.08.2011 | [2013/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2561888 | Date: | 27.02.2013 | Language: | EN | [2013/09] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 20.02.2012 | Classification | IPC: | A61K38/39, A61K47/48 | [2013/09] | CPC: |
A61K38/39 (EP,US);
G01N33/57484 (US);
A61K47/6883 (EP,US);
A61P1/00 (EP);
A61P1/04 (EP);
A61P17/00 (EP);
A61P17/02 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P21/00 (EP);
A61P27/02 (EP);
A61P27/06 (EP);
A61P29/00 (EP);
A61P3/10 (EP);
A61P31/02 (EP);
A61P31/04 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P35/04 (EP);
A61P37/06 (EP);
A61P41/00 (EP);
A61P9/00 (EP);
A61P9/10 (EP);
C07K14/435 (US);
C07K14/78 (EP,US);
C07K2319/00 (EP,US);
C07K2319/21 (EP,US);
C07K2319/30 (EP,US);
C07K2319/50 (EP,US);
G01N2500/04 (US);
G01N2500/10 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/09] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | Protein enthaltend NC-1 zur Behandlung von Erkrankungen in Bezug auf Angiogenese | [2013/09] | English: | Protein comprising NC-1 for treating angiogenesis-related diseases | [2013/09] | French: | Protéine comprenant NC-1 pour traiter des maladies liées à l'angiogenèse | [2013/09] | Examination procedure | 28.08.2013 | Application deemed to be withdrawn, date of legal effect [2014/10] | 04.10.2013 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2014/10] | Fees paid | Penalty fee | Additional fee for renewal fee | 31.08.2013 | 03   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO9962944 (CHILDRENS MEDICAL CENTER [US]) [X] 1-10,17,18 * examples 1,5; claim - *; | [X]WO2006048252 (UNIV MADRID AUTONOMA [ES], et al) [X] 1-18 * figure -; claims 13-27 *; | [XDY]US2006251699 (FOLKMAN JUDAH [US], et al) [XD] 10,17,18 * paragraph [0006]; claims 15-22 * * paragraph [0044] - paragraph [0045] * [Y] 1-18; | [XY]US2007015242 (AZAR DIMITRI T [US], et al) [X] 10,17,18 * paragraph [0006]; figure 1B; claims 7-12 * [Y] 1-18; | [X]US2008269135 (RETSKY MICHAEL W [US]) [X] 1-9 * paragraph [0039]; claim 7 *; | [XY]WO2009003145 (UNIV MIAMI [US], et al) [X] 1,8-10,17,18 * figure 1; claim - * [Y] 1-18; | [X] - SANCHEZ-AREVALO LOBO VICTOR J ET AL, "Enhanced antiangiogenic therapy with antibody-collagen XVIII NCl domain fusion proteins engineered to exploit matrix remodeling events", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, (20060701), vol. 119, no. 2, doi:10.1002/IJC.21851, ISSN 0020-7136, pages 455 - 462, XP009107338 [X] 1-18 * abstract * DOI: http://dx.doi.org/10.1002/ijc.21851 | [X] - HELJASVAARA R ET AL, "Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, (20050715), vol. 307, no. 2, doi:10.1016/J.YEXCR.2005.03.021, ISSN 0014-4827, pages 292 - 304, XP004927161 [X] 1-9 * figure 4 * DOI: http://dx.doi.org/10.1016/j.yexcr.2005.03.021 | [XY] - K. JAVAHERIAN, "Laminin Modulates Morphogenic Properties of the Collagen XVIII Endostatin Domain", JOURNAL OF BIOLOGICAL CHEMISTRY, (20021115), vol. 277, no. 47, doi:10.1074/jbc.M206358200, ISSN 0021-9258, pages 45211 - 45218, XP055018519 [X] 10,17,18 * page 45211, column r * * page 45212, column r * [Y] 1-18 DOI: http://dx.doi.org/10.1074/jbc.M206358200 | [Y] - SASAKI T ET AL, "Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, (20000901), vol. 301, no. 5, doi:10.1006/JMBI.2000.3996, ISSN 0022-2836, pages 1179 - 1190, XP004461690 [Y] 1-18 * page 1184, column r; table 3 * DOI: http://dx.doi.org/10.1006/jmbi.2000.3996 | [Y] - KUO CALVIN J ET AL, "Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain", JOURNAL OF CELL BIOLOGY, (20010319), vol. 152, no. 6, ISSN 0021-9525, pages 1233 - 1246, XP002668991 [Y] 1-18 * abstract * DOI: http://dx.doi.org/10.1083/jcb.152.6.1233 | by applicant | - O'REILLY ET AL., CELL, (1997), vol. 88, page 277 | - FOLKMAN ET AL., EXP CELL RES, (2006), vol. 312, page 594 | - BERGERS ET AL., SCIENCE, (1999), vol. 284, page 808 | - LEE ET AL., CLIN CANCER RES, (2008), vol. 14, page 1487 | - BOEHM ET AL., BIOCHEM BIOPHYS RES COMMUN, (1998), vol. 252, page 190 | - TJIN ET AL., CANCER RES, (2005), vol. 65, page 3656 | - SIM ET AL., ANGIOGENESIS, (1999), vol. 3, page 41 | - LING ET AL., BIOCHEM BIOPHYS RES COM, vol. 361, page 79 | - GORDON ET AL., J CLIN ONCOL, (2001), vol. 19, page 843 | - HOLASH ET AL., PROC NATL ACAD SCI USA, (2002), vol. 99, page 11393 | - LI ET AL., ASIAN PAC J CANCER PREV., (2010), vol. 11, pages 1119 - 23 | - OH ET AL., PNAS, (1994), vol. 91, page 4229 | - GENOMICS, (1994), vol. 19, page 494 | - ABE ET AL., BIOCHEM BIOPHYS RES COMMUN, (1993), vol. 196, page 576 | - SASAKI ET AL., EMBO J, (1998), vol. 17, page 4249 | - DING ET AL., PNAS, (1998), vol. 95, page 10443 | - BOEHM ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1998), vol. 252, page 190 | - KUO, JCB, (2001), vol. 152, page 1233 | - HELIASVAARA ET AL., EXP CELL RES, (2005), vol. 307, page 192 | - ABDOLLAHI ET AL., CANCER RES., (2003), vol. 63, page 8890 | - MOL. CELL, (2004), vol. 13, page 649 | - PNAS, (2007), vol. 104, page 12890 | - DRUG REIST. UPDATE, (2005), vol. 8, page 59 | - JAVAHERIAN ET AL., J. BIOL. CHEM., (2002), vol. 277, page 45211 | - DAMODARAN, FEE, EUROPEAN PHARMACEUTICAL REVIEW, (2010), vol. 15, page 18 | - LO ET AL., PROTEIN ENG, (1998), vol. 11, page 495 | - CAPON ET AL., NATURE, (1989), vol. 337, page 525 | - ALTSCHUL, J MOL BIOL, (1990), vol. 215, page 403 | - HIGGINS, CABIOS, (1989), vol. 5, page 151 | - NEEDLEMAN, J MOL BIOL, (1970), vol. 48, page 443 | - SMITH, ADV APPL MATH, (1981), vol. 2, page 482 | - LO, PROTEIN ENG, (1998), vol. 11, page 495 | - KUO ET AL., 7 CELL BIOL, (2001), vol. 152, page 1233 | - WEN ET AL., CANCER RES, (1999), vol. 59, page 1233 | - ITALIANO ET AL., BLOOD, (2008), vol. 111, page 1227 | - WIJELATH ET AL., CIRC RES, (2006), vol. 99, page 853 | - HYNES, CELL, (1992), vol. 69, page 11 | - JAVAHERIAN ET AL., J BIOL CHENI, (2002), vol. 277, page 45211 | - YI ET AL., PNAS, (2003), vol. 100, page 11435 | - REHN ET AL., PNAS, (2001), vol. 98, page 1024 | - WICKSTROM, CANCER RES, (2002), vol. 62, page 5580 | - ABDOLLAHI ET AL., MOL CELL, (2004), vol. 13, page 649 |